Redeye initiates coverage of NextCell Pharma, a clinical-stage biotech company developing a cell therapy with disease-modifying potential in type 1 diabetes. Strong clinical data and upcoming phase II readouts in 2025–2026 could pave the way for an outlicensing deal, yet the valuation remains modest—offering a compelling opportunity.
LÄS MER
